{
  "case_id": "MN03-2538",
  "year": 2003,
  "patient_info": {
    "age_range": "51 to 64",
    "gender": "Female"
  },
  "diagnosis": "Immuno Disorders",
  "secondary_conditions": [],
  "complications": [],
  "symptoms": [
    "fatigue"
  ],
  "treatment_category": "Pharmacy",
  "treatment_subcategory": "Non-FDA Approved Use",
  "treatments_requested": [
    {
      "name": "Modafinil",
      "drug_type": "other",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": "Requested for SLE associated fatigue"
    }
  ],
  "treatments_tried_but_failed": [],
  "treatments_tried_and_worked": [],
  "treatments_not_tried": [],
  "is_denial_upheld": false,
  "issues_considered": [
    "medical_necessity"
  ],
  "other_issues": null,
  "guidelines_support": null,
  "guidelines_not_support": null,
  "guidelines_details": null,
  "soc_support": null,
  "soc_not_support": null,
  "soc_details": null,
  "study_support": null,
  "study_details": [],
  "key_questions": [
    "medical_necessity"
  ],
  "expedited": false,
  "rationale": "The physician reviewer determined that Provigil is medically necessary for the treatment of the enrollee\u2019s systemic lupus erythematosus (SLE) associated fatigue, overturning the Health Plan's denial.",
  "reviewer_credentials": null
}